source
- Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialGedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.BioPharma Dive · 1mo ago↗ source
- Lilly gives hospitals deadline to comply with 340B claims data policyEli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts. Some health centers aren’t cooperating with Lilly's recent push to…Endpoints · 1mo ago↗ source
- FDA details flexibilities for new cell and gene therapies to leverage past dataThe FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER…